**ImmuneOnco Biopharmaceuticals (Shanghai) Announces Phase III Trial Application for IMM2510 in Lung Cancer** ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. has announced the submission of an application to begin Phase III clinical trials of its investigational drug IMM2510 (palverafusp α) for the treatment of immunotherapy-resistant non-small cell lung cancer (NSCLC) in China. The application was recently submitted to the Center for Drug Evaluation of the National Medical Products Administration (NMPA) and targets different types of lung cancer. Data from a Phase I study presented at the 2025 World Conference on Lung Cancer showed promising results, with IMM2510 achieving a 35.3% objective response rate and a 76.5% disease control rate. Under a license and collaboration agreement, ImmuneOnco holds commercial rights for IMM2510 in Greater China, while Axion Bio, Inc. (a subsidiary of Instil Bio, Inc.) has exclusive rights to develop and commercialize the drug outside the region. No new grant or funding has been announced in connection with this regulatory milestone. The company cautions that successful marketing of IMM2510 is not guaranteed.